Cerenome, Inc. (CNSY) - Total Assets
Based on the latest financial reports, Cerenome, Inc. (CNSY) holds total assets worth $14.03 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how efficiently does Cerenome, Inc. generate cash for how efficiently the company converts equity into cash flow.
Cerenome, Inc. - Total Assets Trend (1998–2025)
This chart illustrates how Cerenome, Inc.'s total assets have evolved over time, based on quarterly financial data. See CNSY live share price for real-time trading data and today's change.
Cerenome, Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Cerenome, Inc.'s total assets of $14.03 Million consist of 92.9% current assets and 7.1% non-current assets. Explore CNSY net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 53.7% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $333.00K | 2.0% |
| Goodwill | $372.00K | 2.3% |
Asset Composition Trend (1998–2025)
This chart illustrates how Cerenome, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cerenome, Inc.'s current assets represent 92.9% of total assets in 2025, an increase from 3.4% in 1998.
- Cash Position: Cash and equivalents constituted 53.7% of total assets in 2025, up from 3.4% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 2.3% of total assets.
Cerenome, Inc. Competitors by Total Assets
Key competitors of Cerenome, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $2.19 Billion |
|
Dyne Therapeutics Inc
NASDAQ:DYN
|
USA | $1.08 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Recursion Pharmaceuticals Inc
NASDAQ:RXRX
|
USA | $1.21 Billion |
|
LegoChem Biosciences Inc
KQ:141080
|
Korea | ₩652.93 Billion |
Cerenome, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.37 | 1.26 | 2.33 |
| Quick Ratio | 1.37 | 1.26 | 2.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $3.20 Million | $1.90 Million | $12.61 Million |
Cerenome, Inc. - Advanced Valuation Insights
This section examines the relationship between Cerenome, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.83 |
| Latest Market Cap to Assets Ratio | 0.90 |
| Asset Growth Rate (YoY) | 146.1% |
| Total Assets | $16.32 Million |
| Market Capitalization | $14.65 Million USD |
Valuation Analysis
Near Book Valuation: The market values Cerenome, Inc.'s assets close to their book value (0.90x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Cerenome, Inc.'s assets grew by 146.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Cerenome, Inc. (1998–2025)
The table below shows the annual total assets of Cerenome, Inc. from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $16.32 Million | +146.12% |
| 2024-12-31 | $6.63 Million | -41.75% |
| 2023-12-31 | $11.39 Million | -52.29% |
| 2022-12-31 | $23.87 Million | +8.58% |
| 2021-12-31 | $21.98 Million | +81.59% |
| 2020-12-31 | $12.11 Million | -47.89% |
| 2019-12-31 | $23.23 Million | -3.18% |
| 2018-12-31 | $23.99 Million | -24.12% |
| 2017-12-31 | $31.61 Million | -8.65% |
| 2016-12-31 | $34.61 Million | -10.61% |
| 2014-12-31 | $38.72 Million | -7.94% |
| 2013-12-31 | $42.06 Million | -2.75% |
| 2012-12-31 | $43.25 Million | -16.07% |
| 2011-12-31 | $51.53 Million | -22.33% |
| 2010-12-31 | $66.35 Million | +168.08% |
| 2009-12-31 | $24.75 Million | -3.36% |
| 2008-12-31 | $25.61 Million | +19.07% |
| 2007-12-31 | $21.51 Million | -13.52% |
| 2006-12-31 | $24.87 Million | -11.71% |
| 2005-12-31 | $28.17 Million | +10.59% |
| 2004-12-31 | $25.47 Million | -9.32% |
| 2003-12-31 | $28.09 Million | -28.56% |
| 2002-12-31 | $39.32 Million | -8.86% |
| 2001-12-31 | $43.14 Million | -17.46% |
| 2000-12-31 | $52.27 Million | +837.56% |
| 1999-12-31 | $5.58 Million | +446.57% |
| 1998-12-31 | $1.02 Million | -- |
About Cerenome, Inc.
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cance… Read more